CNTB · CIK 0001835268 · operating
Connect Biopharma is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company's lead product candidate, rademikibart (formerly CBP-201), is a monoclonal antibody targeting interleukin-4 receptor alpha currently in Phase 3 clinical development. The program is being evaluated for treatment of atopic dermatitis and asthma, both conditions characterized by dysregulated immune responses.
As a preclinical and clinical-stage company, Connect Biopharma has not yet generated product revenues. The company operates primarily through research and development activities supporting its antibody development pipeline. Operations are centered in San Diego, California, where the company maintains its headquarters and core research team.
The company operates with a lean structure of 62 full-time employees, typical for clinical-stage biotechnology firms focused on single or limited product candidates. Connect Biopharma was incorporated in the Cayman Islands and founded in 2012, with shares listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.28 | $-0.28 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-31 | 0001835268-25-000014 | SEC ↗ |